PharmaCyte Biotech Sets 1-for-19 Reverse Stock Split, Effective Nov. 12
Split-adjusted trading began Nov. 13 under the unchanged ticker PMCB, with a new CUSIP of 71715X302.

Key terms
- 1-for-19 reverse split effective 4:01 p.m. ET on Nov. 12, 2026
- Split-adjusted trading began Nasdaq open on Nov. 13, 2026; ticker stays PMCB
- New CUSIP 71715X302; fractional shares paid in cash
- Shares outstanding to fall from about 10,755,649 to about 566,087
PharmaCyte Biotech (Nasdaq: PMCB) has effected a 1-for-19 reverse stock split, the company said in an 8-K filed Friday, Nov. 13.
The split took effect at 4:01 p.m. Eastern Time on Nov. 12. Common stock began trading on a split-adjusted basis when The Nasdaq Capital Market opened on Nov. 13. The ticker remains PMCB, but the CUSIP number changes to 71715X302.
Every 19 shares of common stock were combined into one share, with the par value unchanged at $0.0001. Shares outstanding will fall from about 10,755,649 as of Nov. 11 to about 566,087. The number of authorized shares is not changed. Options, warrants, convertible securities and equity plan share counts were adjusted proportionally.
No fractional shares will be issued. Holders who would otherwise receive a fraction will get a cash payment in lieu of it, equal to the fractional amount multiplied by the closing price on Nov. 12, adjusted for the split.
Why the company is doing it
The company said the split is intended to increase the per-share trading price so it can regain compliance with the Nasdaq minimum bid price requirement for continued listing. Stockholders approved a split ratio between 1-for-1.1 and 1-for-100 at the annual meeting on March 30, 2026, and the board chose 1-for-19.
What holders will see
Shares held electronically or through a bank or broker are adjusted automatically, and the company said those holders do not need to take any action. Holders of physical stock certificates will receive instructions from transfer agent Equiniti Trust Company, LLC on exchanging them for post-split shares or book-entry positions.
Sources
Written with AI from the company's SEC filing and our market data, and checked against those sources before publishing. Our editorial standards.
More corporate actions
Reverse stock splits and stock splits →- Sandisk Sets 8-for-1 Forward Stock Split, Trading Split-Adjusted Nov. 20 · SNDK · Nov. 19, 2026
- Lisata Therapeutics Sets 1-for-15 Reverse Stock Split, Effective Nov. 23 · LSTA · Nov. 19, 2026
- SmartKem Sets 1-for-5 Reverse Stock Split, Effective Nov. 20 · SMTK · Nov. 19, 2026
- Air Industries Group Will Not Carry Out 1-for-5 Reverse Stock Split · AIRI · Nov. 19, 2026
More on PharmaCyte Biotech
PMCB page →Filings, figures and price history are on the PharmaCyte Biotech page.